802536-13-6 Usage
Explanation
This is the full chemical name of the compound, which describes its structure and components.
Explanation
The compound contains a pyrazoloquinazoline core structure, which is the central framework of the molecule.
Explanation
It is a chemical compound, which means it is a substance formed from two or more elements chemically bonded together.
Explanation
The compound acts as a potent and selective inhibitor of the enzyme PARP, which is involved in DNA repair.
Explanation
By inhibiting PARP, the compound prevents the repair of damaged DNA, leading to the death of cancer cells.
Explanation
The compound has shown potential anticancer activity in preclinical studies, making it a candidate for further investigation.
Explanation
The compound is being investigated for its potential use in treating different types of cancer due to its unique structure and mechanism of action.
Explanation
The compound's unique structure and mechanism of action make it a promising candidate for the development of new cancer therapies.
Core Structure
Pyrazoloquinazoline
Classification
Chemical Compound
Target Enzyme
Poly(ADP-ribose) polymerase (PARP)
Role in DNA Repair
Inhibition
Anticancer Activity
Promising
Cancer Treatment Potential
Various types of cancer
Development
Novel cancer therapies
Check Digit Verification of cas no
The CAS Registry Mumber 802536-13-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,0,2,5,3 and 6 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 802536-13:
(8*8)+(7*0)+(6*2)+(5*5)+(4*3)+(3*6)+(2*1)+(1*3)=136
136 % 10 = 6
So 802536-13-6 is a valid CAS Registry Number.
802536-13-6Relevant articles and documents
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitor
Traquandi, Gabriella,Ciomei, Marina,Ballinari, Dario,Casale, Elena,Colombo, Nicoletta,Croci, Valter,Fiorentini, Francesco,Isacchi, Antonella,Longo, Antonio,Mercurio, Ciro,Panzeri, Achille,Pastori, Wilma,Pevarello, Paolo,Volpi, Daniele,Roussel, Patrick,Vulpetti, Anna,Brasca, Maria Gabriella
experimental part, p. 2171 - 2187 (2010/08/19)
Abnormal proliferation mediated by disruption of the mechanisms that keep the cell cycle under control is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDKs) and cyclins (Cy) and inhibiting their activity are regarded as promising antitumor agents to complement the existing therapies. An expansion of pyrazolo[4,3-h]quinazoline chemical class oriented to the development of three points of variability was undertaken leading to a series of compounds able to inhibit CDKs both in vitro and in vivo. Starting from the CDK selective but poorly soluble hit compound 1, we succeeded in obtaining several compounds showing enhanced inhibitory activity both on CDKs and on tumor cells and displaying improved physical properties and pharmacokinetic behavior. Our study led to the identification of compound 59 as a highly potent, orally bioavailable CDK inhibitor that exhibited significant in vivo efficacy on the A2780 ovarian carcinoma xenograft model. The demonstrated mechanisms of action of compound 59 on cancer cell lines and its ability to inhibit tumor growth in vivo render this compound very interesting as potential antineoplastic agent.